S80492 |
Zibotentan (ZD4054) |
源葉(MedMol) | 98% |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.356 ml | 11.781 ml | 23.561 ml |
5 mM | 0.471 ml | 2.356 ml | 4.712 ml |
10 mM | 0.236 ml | 1.178 ml | 2.356 ml |
50 mM | 0.047 ml | 0.236 ml | 0.471 ml |
- 提示:詳情請下載說明書。
- 產(chǎn)品描述: Zibotentan (ZD4054) is a potent, selective and orally active endothelin A (ETA) receptor antagonist with a Ki of 13 nM. Zibotentan has no inhibitory effect on ETB. Zibotentan has anticancer effects and can be used for castration-resistant prostate cancer (CRPC) research
- 靶點: ETA:13 nM (Ki);Apoptosis;EndothelinReceptor
- 體內(nèi)研究:
Zibotentan (10 mg/kg; intraperitoneal injection; daily; for 21 days) treatment significantly inhibits tumor growth in mice. And Zibotentan treatment increases E-cadherin expression
- 參考文獻:
1. C D Morris, et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer. 2005 Jun 20;92(12):2148-52. 2. Laura Rosanò, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011 Apr 15;17(8):2350-60. 3. Laura Rosanò, et al. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther. 2007 Jul;6(7):2003-11.
- 溶解性: Soluble in DMSO
- 保存條件: -20℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 2.356 ml 11.781 ml 23.561 ml 5 mM 0.471 ml 2.356 ml 4.712 ml 10 mM 0.236 ml 1.178 ml 2.356 ml 50 mM 0.047 ml 0.236 ml 0.471 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:
本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:
質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)